Literature DB >> 6274467

Radioprotection of mouse skin by WR-2721 in single and fractionated treatments.

F A Stewart, A Rojas.   

Abstract

The radioprotective action of WR-2721 on mouse skin has been studied using single doses, two and five fractions. Significant radioprotection was observed with 200-500 mg/kg, in animals breathing air or oxygen at the time of irradiation. The degree of radioprotection increased with increasing dose, and was significantly greater in air than in oxygen, especially at low drug doses. Cumulative drug toxicity limited the fractionated treatments to lower drug doses, but the protection observed was similar to that seen with single doses at the same drug levels. The protection factors observed are lower than many published values for skin, and we conclude that a single protection factor cannot yet be stated for any dose of WR-2721. Local tissue oxygenation may account for some of the discrepancies in different studies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6274467     DOI: 10.1259/0007-1285-55-649-42

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  4 in total

1.  Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.

Authors:  J J Varghese; I L Schmale; D Mickelsen; M E Hansen; S D Newlands; D S W Benoit; V A Korshunov; C E Ovitt
Journal:  J Dent Res       Date:  2018-04-10       Impact factor: 6.116

Review 2.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

3.  The effect of misonidazole combined with WR2721 on tumour response and leucopenia due to cyclophosphamide or melphalan.

Authors:  N J McNally
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

4.  Interaction of radiosensitizers and WR-2721. I. Modification of skin radioprotection.

Authors:  A Rojas; F A Stewart; J Denekamp
Journal:  Br J Cancer       Date:  1982-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.